Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shanghai Henlius Biotech Co. Ltd.

https://www.henlius.com/en/index.html

Latest From Shanghai Henlius Biotech Co. Ltd.

Henlius Finds Global Partner For Ophthalmic Bevacizumab

Shanghai Henlius Biotech has struck a co-development and licensing deal with fellow Chinese firm Essex Bio-Technology for biosimilar bevacizumab to treat ophthalmic diseases.

Biosimilars Deals

Cancer, Rare Disease Drugs Among New China Approvals

Rare disease and cancer treatments are front and center in the latest batch of China new drug approvals, while biosimilars are expected to move into the spotlight.

Approvals China

Henlius’ Trastuzumab Approved In China

Shanghai Henlius Biotech has received the first Chinese approval for a trastuzumab biosimilar version of Herceptin.

Biosimilars Approvals

Accord Adds To Crowded EU Trastuzumab Market

Shanghai Henlius Biotech is to make history with the first China-developed monoclonal antibody biosimilar in Europe, the firm’s Zercepac (trastuzumab) biosimilar that has been licensed to Accord Healthcare.

Biosimilars Approvals
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • Fosun Pharma
    • Henlius Biopharmaceuticals
    • Shanghai Henlius Biotech, Inc.
    • Taiwan Henlix Biotech Co., Ltd.
    • Hengenix Biotech
UsernamePublicRestriction

Register